Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

FPC Capital Requirements

20 Jun 2013 07:08

RNS Number : 4621H
Royal Bank of Scotland Group PLC
20 June 2013
 



 

 

The Royal Bank of Scotland Group plc

 

20 June 2013

 

Statement on the completion of the UK Regulators capital shortfall exercise

 

The Royal Bank of Scotland Group plc ("RBS", "the Group") notes today's announcement by the Prudential Regulatory Authority ("PRA") on the completion of its capital shortfall exercise across major UK banks and building societies.

 

As indicated in its earlier release, dated 22 May, RBS expects to continue to improve its Core Tier 1 capital ("CT1") ratio during 2013 through continued delivery against its established business plan.

 

RBS continues to target a 'fully loaded' Basel 3 CT1 ratio of around 9% by year end 2013, after including the provision of capital to fund anticipated future loan growth.

 

Further details of RBS's plans and a reconciliation to the results published by the PRA today are provided below in the Appendix to this announcement.

 

For further information contact:

 

RBS Group Investor Relations

Richard O'Connor

Head of Investor Relations

+44 207 672 1758

RBS Group Media Relations

Michael Strachan

Deputy Head of Group Media Relations

+44 131 523 4205

 

Appendix to statement:

Reconciliation with RBS Group plc published ratios and 2013 glidepath

 

The PRA's original assessment of RBS's capital adequacy, under the FPC's recommendations, is outlined in the table below. RBS's position, factoring in business plans and actions announced at the FY12 results and Q113 IMS, is presented alongside this.

RBS's position takes into account the Group's previously announced repositioning of its Markets business and the planned continued reduction of Non-Core exposures, as well as other actions. While the Group's intention to partially IPO Citizens was announced in consideration of the PRA capital exercise, it is not factored into the 2013 capital actions.

The principal adjustments that RBS applied to the PRA December 2012 start point are:

1) the RBS assumption around counterparty credit model acceptance that a) brings RBS in line with peers and b) has been worked on for two years, with acceptance expected prior to CRDIV implementation at the start of 2014;

2) Latest Capital Requirements Directive IV ("CRDIV") changes, which exempt EU corporates, pension funds and sovereign exposures from CVA volatility charge, confirmation of which was announced post the original PRA analysis.

By the end of 2013, the PRA capital requirement under the FPC exercise of £3.2bn is targeted to be reduced to £0.4bn. Several actions contribute to this including Markets downsizing, several small planned divestments and LME gains.

 

 

 

 

 

RBS capital requirements compared to PRA view

Reference

Per PRA

RBS

 

£bn

£bn

End 2012 position

Core Capital Resources (CET1 Basel 3)

37.2

Reported RWAs (Basel 3)

567.9

End 2012 CET1 Ratio

6.5%

Known capital adjustments

Note 2

1.0

Known/expected RWA adjustments

Note 3

(72.9)

Core Capital Resources (CET1 Basel 3)

38.2

Reported RWAs (Basel 3)

495.0

CET1 Ratio (as published by RBS)

Note 1

7.7%

PRA adjustments

PRA adjustments to capital resources for expected future losses and an assessment of future cost of conduct redress

(7.1)

(7.1)

PRA adjustments to RWAs to reflect a more prudent calculation of risk weights

56.3

56.3

Capital actions

Total CET1 equivalent of capital actions required of RBS

13.6

7.5

CET1 equivalent actions in RBS's plans

10.4

7.1

Additional capital action requirement planned by RBS to meet the PRA 7% as of December 2013

Note 4

3.2

0.4

 

 

Note 1: CET1 Basel 3 capital position as of December 2012

Reference

Capital

RWA

%

£bn

£bn

PRA

37.2

567.9

6.5%

Adjustments:

 

- Capital base changes

Note 2

1.0

0.2%

- Counterparty risk IMM model extension

Note 3

(47.0)

0.6%

- Reduction in counterparty risk due to CRDIV CVA changes

Note 3

(36.0)

0.5%

- Other

Note 3

10.1

(0.1)%

RBS (as published)

a

38.2

495

7.7%

 

 

a Note that Deferred Tax Asset deduction is taken in full: with an impact of 70bps on CT1. The real capital benefit of this asset for RBS will emerge over the next 5 years as the Group returns to profitability.

 

 

 

Note 2: The end 2012 capital base variance of £1bn is due to:

 

i) securitisation treated as RWAs rather than a deduction;

ii) offset principally by higher actual provisions taken in Q4 2012 for conduct risk relative to forecast used by the PRA.

 

Note 3: The RWA adjustment of £72.9bn represents RBS assumption around counterparty credit model acceptance that a) brings RBS in line with peers and b) has been worked on for two years with approval expected shortly; and latest CRDIV changes reflected by RBS but not by the PRA given timing of the exercise. In addition, this also includes impact of securitisation treated as RWA rather than a deduction.

Reference

£bn

£bn

 

RWAs per PRA (Dec-12 Flash)

567.9

Counterparty risk IMM model extension

(47.0)

Reduction in counterparty risk due to CRDIV text changes

b

(36.0)

Net Other (including securitisation treated as RWA)

10.1

(72.9)

RWAs - as adjusted

495.0

 

 

Note 4: RBS actions to address remaining gap

Factoring in business plans announced at the FY12 results, Q113 IMS and remaining planned capital actions, RBS's capital shortfall reduces to £0.4bn, which the Group plans to fully satisfy in early 2014.

Reference

Per PRA

Per RBS

£bn

£bn

Total Capital actions required

13.6

7.5

Adjustments for models & EU exemptions

(6.1)

-

7.5

7.5

Q1 2013 progress on fully loaded ratio

(2.4)

Q2-Q4 2013 planned actions

RWA reduction (including Non Core rundown & Markets reshape)

(3.0)

Reduction in excess Expected Loss over provision

(1.0)

Other capital movements

c

(0.7)

Total Q2-Q4 2013 planned actions

(4.7)

Total 2013 actions

(7.1)

Post planned actions capital requirement

d

0.4

 

 

 

b CRDIV final text includes exemption for EU corporates, pension funds and sovereigns from CVA volatility charge in RWA calculations.

cCapital base movement includes, among other things, use of consensus profit forecast, expected gains on small disposals and liability management exercises.

d Remaining gap of £0.4bn to be closed through Q1 2014 profit generation and continuing benefits of Markets re-sizing. Planned IPO of Citizens provides further comfort.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCNKKDKABKKQAB
Date   Source Headline
17th Apr 201911:20 amRNSSegmental Reporting Restatement Document
1st Apr 20194:30 pmRNSDirector/PDMR Shareholding
29th Mar 20195:04 pmRNSTotal Voting Rights
27th Mar 20192:05 pmRNSPublication of Final Terms
20th Mar 201910:17 amRNSRBSG pricing of US$2 billion of Senior Notes
19th Mar 20198:30 amRNSMorgan Stanley European Financials Conference
13th Mar 20196:26 pmRNSNotice of Redemption
11th Mar 20193:00 pmRNSDirector/PDMR Shareholding
7th Mar 20194:56 pmRNSForm 8.3 - Findel plc
6th Mar 20192:45 pmRNSForm 8.3 - MedicX Fund Limited
1st Mar 20191:10 pmRNSForm 8.3 - MedicX Fund Limited
1st Mar 201912:01 pmRNSDirector/PDMR Shareholding
1st Mar 20197:00 amRNSFiling of Annual Report on Form 20-F with US SEC
28th Feb 20192:25 pmRNSDividend Declaration
28th Feb 201912:40 pmRNSTotal Voting Rights
26th Feb 20195:50 pmRNSPublication of Supplementary Prospectus
22nd Feb 201912:51 pmRNSUpdate on NatWest Markets transfer scheme
22nd Feb 201912:00 pmRNSDirector/PDMR Shareholding
15th Feb 20193:00 pmRNSPublication of Supplementary Prospectus
15th Feb 20197:02 amRNSDirectorate Change
15th Feb 20197:01 amRNSAnnual Financial Report
15th Feb 20197:00 amRNSFinal Results
6th Feb 20194:16 pmRNSResult of Meeting
6th Feb 20192:55 pmRNSGM Statement
31st Jan 201911:42 amRNSTotal Voting Rights
29th Jan 20192:55 pmRNSDirector/PDMR Shareholding
25th Jan 20191:27 pmRNSForm 8.3 Disclosure
17th Jan 20194:10 pmRNSNotice of GM
9th Jan 20195:02 pmRNSHolding(s) in Company
31st Dec 20181:13 pmRNSTotal Voting Rights
28th Dec 20184:28 pmRNSDirector/PDMR Shareholding
27th Dec 20184:55 pmRNSDividend Declaration
18th Dec 20183:55 pmRNSDirectorate Change
14th Dec 20186:15 pmRNSRBS welcome credit ratings action by Fitch Ratings
14th Dec 20183:33 pmRNSPublication of a Prospectus
6th Dec 20184:40 pmRNSSecond Price Monitoring Extn
6th Dec 20184:35 pmRNSPrice Monitoring Extension
6th Dec 20182:16 pmRNSNatWest Markets transfer scheme
30th Nov 20182:30 pmRNSTotal Voting Rights
30th Nov 20181:12 pmRNSDirector/PDMR Shareholding
29th Nov 20184:28 pmRNSDividend Declaration
29th Nov 20184:07 pmRNSNotice of Redemption
29th Nov 201811:34 amRNSNotice of Rdemption
29th Nov 201811:33 amRNSNotice of Redemption
29th Nov 201811:31 amRNSNotice of Redemption
29th Nov 201811:31 amRNSNotice of Redemption
29th Nov 20188:00 amRNSRBS Investor Seminar: Commercial Banking
28th Nov 20185:09 pmRNS2018 Bank of England stress test results
16th Nov 201812:00 pmRNSDirector/PDMR Shareholding
9th Nov 20184:16 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.